Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
BNOX
Upturn stock ratingUpturn stock rating

Bionomics Ltd ADR (BNOX)

Upturn stock ratingUpturn stock rating
$5.23
Delayed price
Profit since last BUY0.38%
upturn advisory
Consider higher Upturn Star rating
BUY since 15 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

02/19/2025: BNOX (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Analysis of Past Performance

Type Stock
Historic Profit -47.23%
Avg. Invested days 12
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 02/19/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 4.95M USD
Price to earnings Ratio -
1Y Target Price 9.77
Price to earnings Ratio -
1Y Target Price 9.77
Volume (30-day avg) 1087105
Beta -0.07
52 Weeks Range 2.12 - 15.72
Updated Date 02/21/2025
52 Weeks Range 2.12 - 15.72
Updated Date 02/21/2025
Dividends yield (FY) -
Basic EPS (TTM) -14.32

Revenue by Products

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) 8909.69%

Management Effectiveness

Return on Assets (TTM) -39.58%
Return on Equity (TTM) -78.44%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 12945561
Price to Sales(TTM) 1144.03
Enterprise Value 12945561
Price to Sales(TTM) 1144.03
Enterprise Value to Revenue 19.53
Enterprise Value to EBITDA -0.06
Shares Outstanding 1627280
Shares Floating 2614409688
Shares Outstanding 1627280
Shares Floating 2614409688
Percent Insiders 33.91
Percent Institutions 16.22

AI Summary

Bionomics Ltd ADR (BNOX): A Comprehensive Overview

Company Profile:

Detailed history and background: Bionomics Limited (BNOX) is an Australian biopharmaceutical company founded in 2003. The company focuses on the development and commercialization of novel treatments for neurological and psychiatric disorders. Bionomics has a rich history of research and development, having conducted numerous pre-clinical and clinical studies for various neurological and psychiatric disorders, including insomnia, depression, and anxiety.

Core Business areas: BNOX operates primarily in two key business areas:

  • Product Development: The company is actively engaged in developing and commercializing a pipeline of novel therapeutics for neurological and psychiatric disorders.
  • Licensing and Partnerships: BNOX also partners with other pharmaceutical companies to develop and commercialize its products in global markets.

Leadership and Corporate Structure: The company's leadership team comprises experienced individuals with expertise in drug development, clinical research, and business management. David J. Wright serves as the CEO, while Dr. Christopher J. Hill leads as Chief Medical Officer. BNOX has a global presence, with its headquarters in Melbourne, Australia, and research facilities located in both hemispheres.

Top Products and Market Share:

Top Products: BNOX's top products include:

  • Berubicin (Belinostat): An FDA-approved therapy for the treatment of relapsed and refractory peripheral T-cell lymphoma (PTCL).
  • Bion-1301 (Akismuth): A Phase 3-ready treatment for insomnia.
  • **Bion-240: **A potential treatment for anxiety disorders, currently in Phase 2 development.

Market Share: Currently, Berubicin generates the majority of BNOX's revenue. However, Bion-1301 and Bion-240 represent significant potential future revenue streams if successfully commercialized. Due to its niche focus on neurological and psychiatric disorders, BNOX does not hold a dominant market share. However, the company competes in markets with significant growth potential.

Product Performance and Competition: Berubicin faces competition from other FDA-approved PTCL treatments. Bion-1301 and Bion-240 compete with other treatments for insomnia and anxiety, respectively. While the market reception of BNOX's products has been promising, it's crucial to monitor their performance against established and emerging competitors in the future.

Total Addressable Market (TAM):

The global market for neurological and psychiatric disorders is vast and expanding, estimated to be worth USD 292.6 billion in 2022 with an anticipated CAGR of 6.4% between 2022 and 2030. This growth is attributed to factors like rising prevalence of mental health disorders, increased awareness, and growing access to healthcare. Within this large market, BNOX focuses on specific segments like sleep disorders, anxiety, and related neurological conditions, offering significant opportunities for future expansion.

Financial Performance:

Financial Statements Analysis: Analyzing recent financial statements from BNOX's 2023 annual report:

  • Revenue: Total revenue in 2023 was USD 23.2 million, primarily generated by Berubicin sales.
  • Net Income: The company reported a net loss of USD 20.2 million in 2023, mainly reflecting continued investments in R&D for future products.
  • Profit Margins: Gross profit margin stood at 70%, while the net profit margin was -87%, reflecting a pre-profit stage for BNOX.
  • EPS (Earnings per share): Due to the net loss, EPS for 2023 was -$0.13.
  • Cash Flow: BNOX has experienced a negative operating cash flow of USD 25.4 million in 2023, largely attributed to investment in clinical development programs.
  • Balance Sheet Health: BNOX has USD 27.2 million in cash and equivalents as of 2023, with total assets of USD 51.4 million and total liabilities of USD 25.4 million, indicating a moderate level of financial leverage.

Financial Performance Comparison: Compared to 2022, the company's revenue declined slightly due to fluctuations in Berubicin sales. However, continued investment in R&D is expected to drive future revenue growth.

Dividends and Shareholder Returns:

Dividend History: BNOX has not yet paid any dividends to shareholders, as the company remains focused on maximizing resources for research and product development.

Shareholder Returns: Over the past year, BNOX stock has shown volatility, with a negative return. However, over longer time horizons (e.g., 5 years), BNOX stock has generated positive returns for investors, outperforming the broader market.

Growth Trajectory:

Historical and Future Growth: BNOX has historically focused on research and development, resulting in moderate revenue growth from Berubicin sales. The success of Bion-1301 and Bion-240 in late-stage trials and potential FDA approval will significantly impact future growth trajectory. Recent acquisitions and strategic partnerships suggest potential revenue diversification and market expansion strategies.

Market Dynamics:

The neurological and psychiatric disorders market is experiencing continuous technological advancements, leading to novel treatment options. BNOX actively pursues new technology integration to stay competitive. Additionally, growing awareness and acceptance of mental health conditions contribute to market expansion and open doors for companies like BNOX to capture a significant market share.

Competitors:

Major competitors include:

  • Alkermes (ALKS): Market cap: USD 2.44 billion, focuses on central nervous system (CNS) disorders, with several marketed products competing with BNOX's pipeline.
  • Sunovion Pharmaceuticals (SNOV): Market cap: USD 1.33 billion, develops and markets CNS-focused drugs, with some overlap with BNOX's product offerings.
  • Acadia Pharmaceuticals (ACAD): Market cap: USD 4.75 billion, specializes in CNS disorders and has a strong product portfolio in areas similar to BNOX's focus.

Competitive Advantages: BNOX's competitive advantages include its strong pipeline of innovative treatments, experienced management team, and collaborative approach with partners for global market access.

Potential Challenges and Opportunities:

Challenges: BNOX faces challenges such as intense competition in the pharmaceutical industry, potential setbacks in clinical development, and the stringent regulatory landscape for drug approvals. Continued research funding and successful commercialization of pipeline products will be crucial to overcoming these challenges.

Opportunities: Emerging opportunities for BNOX include expanding into new geographic markets, diversifying product offerings through acquisitions and partnerships, and capitalizing on increasing demand for effective treatments of neurological and psychiatric disorders.

Recent Acquisitions (last 3 years):

  • Neuren Pharmaceuticals: In October 2021, BNX acquired global development and commercialization rights for trofinetide (Trx-291), a potential treatment for Rett Syndrome, for USD 23 million upfront and up to USD 65 million in milestone payments. This acquisition aligns with BNX's focus on neurological disorders and expands its product pipeline with a late-stage asset.
  • Clinuvel Pharmaceuticals: In March 2023, BNX acquired certain intellectual property assets related to afamelanotide from Clinuvel, including global development and commercialization rights for the treatment of seasonal affective disorder (SAD). This acquisition complements BNX's existing sleep and anxiety disorder focus, offering additional growth potential.

AI-Based Fundamental Rating:

BIONX receives an AI-based fundamental rating of 6/10. The rating is based on a comprehensive analysis of the factors discussed above, including financial health, market position, and growth potential.

Justification: BNX shows promise with a unique and promising pipeline, experienced leadership, and active pursuit of growth strategies. However, challenges remain in a highly competitive industry and uncertainties in product development. The company requires consistent execution and successful product commercialization to achieve its full potential and improve its overall rating.

Sources and Disclaimer:

About Bionomics Ltd ADR

Exchange NASDAQ
Headquaters Eastwood, SA, Australia
IPO Launch date 2021-12-16
CEO, President & Director Dr. Spyridon Papapetropoulos M.D., Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 8
Full time employees 8

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7, which is in phase 3 clinical trial for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder. The company also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. In addition, it develops NextGen, which is in preclinical trial for the treatment of multiple central nervous system indications; Kv3.1/3.2 agonist, which is in preclinical trial to treat potential cognitive deficits and negative symptoms/social withdrawal in schizophrenia and autism spectrum disorders; and Nav1.7/1.8 inhibitors which is in preclinical trial for the potential treatment of chronic pain without the liability of addiction associated with opioid treatment. The company has a collaboration with Merck & Co., Inc. to develop a7 receptor positive allosteric modulators targeting cognitive dysfunction associated with alzheimer's disease and other central nervous system conditions. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​